Zobrazeno 1 - 10
of 55
pro vyhledávání: '"W J, Stuckey"'
Publikováno v:
Cancer Investigation. 12:399-402
Soft tissue sarcomas are generally resistant to most chemotherapeutic agents, and individuals with advanced disease have a poor prognosis. We evaluated amonafide, a new drug that has significant activity against several tumor cell lines, to determine
Autor:
John Wendall Goodwin, W. J. Stuckey, John Crowley, Barthel Barlogie, Robert B. Livingston, Celestia S. Higano
Publikováno v:
Cancer. 67:2439-2442
The purpose of this Phase II pilot study was to determine whether a dose-intensive regimen of weekly cisplatin combined with other active non-cross-resistant agents would improve the response rate and survival time of patients with extensive non-smal
Publikováno v:
Investigational new drugs. 11(2-3)
Fifty-eight evaluable patients with acute leukemia were treated with Mitoxantrone (DHAD) according to two schedules: 14 mg/M2 as a single I.V. pulse dose administered three-week intervals, and 4 mg/M2/day for five days every three weeks. Six of 58 pa
Autor:
Joanne E. Mortimer, W. J. Stuckey, James R. Eltringham, Harmon J. Eyre, Paul L. Weiden, John Crowley
Publikováno v:
Cancer. 69(5)
The Southwest Oncology Group conducted a trial of intra-arterial cisplatin (150 mg intravenously every 21 days for 2 doses) administered concomitant with or before radiation therapy. Because of technical difficulties cannulating the artery, 27 of 33
Publikováno v:
Cancer. 67(10)
The purpose of this Phase II pilot study was to determine whether a dose-intensive regimen of weekly cisplatin combined with other active non-cross-resistant agents would improve the response rate and survival time of patients with extensive non-smal
Publikováno v:
The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society. 143(4)
The Ochsner Medical Institutions of New Orleans and Baton Rouge, the Louisiana State Medical Centers in New Orleans and Shreveport, and the Tulane Medical Center of New Orleans are all actively involved in the conduct of National Cancer Institute app
Autor:
Saul E. Rivkin, Z Steiger, L Leichman, Elizabeth Poplin, Thomas R. Fleming, W. J. Stuckey, Sarah A. Taylor, R Vance, H G Seydel
Publikováno v:
Journal of Clinical Oncology. 5:622-628
Conservative treatment of esophageal cancer with radiation therapy has afforded few long-term survivors. In order to improve outcome, patients with locoregional disease were treated using a combined modality approach. Patients were treated with chemo
Autor:
Richard J Reed, W. J. Stuckey, John N. Bickers, Robert B. Livingston, Joel White, Ronald L. Stephens, Lance K. Heilbrun, Joseph H. Saiers, Joseph D. McCcracken, Michael K. Samson
Publikováno v:
Cancer. 46:2335-2340
From November 1976 to November 1978, the Southwest Oncology Group treated 254 patients with extensive (metastatic) small cell carcinoma of the lung with combination chemotherapy and radiotherapy with and without BCG immunotherapy. Patients receiving
Autor:
J. Whitecar, John J. Costanzi, Teresa J. Vietti, W. J. Stuckey, James S. Hewlett, John H. Saiki, Francis S. Morrison, B. Hoogstraten, Kenneth B. McCredie
Publikováno v:
Cancer. 42:2111-2114
101 patients with acute leukemia in relapse were treated with 5-azacytidine according to three schedules: Regimen A--300 mg/m2(day divided intravenously at 8 hour intervals for 5 days; Regimen B--750 mg/m2 as a single iv pulse dose administered at 2
Autor:
Saul E. Rivkin, Howard S. Levin, Ronald L. Stephens, William S. Fletcher, M. El-Bolkainy, W. J. Stuckey, Lodovico Balducci, Robert Gagliano, Henry E. Wilson, John H. Saiki, Dennis O. Dixon, Robert M. O'Bryan, Charles A. Coltman, John D. Bonnet
Publikováno v:
American Journal of Clinical Oncology. 6:215-218
Patients with advanced transitional cell bladder carcinoma were randomized to receive either adriamycin alone, or adriamycin plus DDP. Overall response (CR + PR) was 8/41 (19%) for adriamycin alone versus 16/37 (43%) for the combination (p = 0.02). M